Managing Director, Cervantes Life Science Partners, LLC
Laura Brege possesses over 35 years’ experience in the financial and healthcare industries, over which time she has held senior positions at a number of high-growth pharmaceutical companies and venture capital firms. During her recent tenure as President and CEO of Nodality, Inc., Laura executed the largest deal in the company’s history. Prior to that, she was the COO of Onyx Pharmaceuticals, Inc., CFO of COR Therapeutics, Inc., and CFO of Flextronics, Inc.
Laura currently serves as a Senior Advisor for BridgeBio Pharma, a clinical-stage biotechnology company developing novel, genetically targeted therapies to improve the lives of patients, and is also Managing Director of Cervantes Life Science Partners, LLC, which helps companies chart, guide and execute plans to build value. She serves as chair/member of the Audit Committee for the boards of five public pharmaceutical companies (Acadia Pharmaceuticals, Inc.; Aratana Therapeutics, Inc.; Dynavax Technologies Corporation; Pacira Pharmaceuticals, Inc.; and Portola Pharmaceuticals, Inc.) and also serves on a number of nonprofit boards. Laura holds degrees in Political Science and Economics from Ohio University and an MBA from the University of Chicago.